Results from clinical trials on ST‐elevation myocardial infarction in a historic perspective with some pathophysiological aspects

References

• Consensus document. Myocardial infarction redefined — A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000; 21: 1502–1513.
   PubMed Web of Science ®Google Scholar
• Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177–1189.
   Google Scholar
• Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Circulation 1998; 97: 211–218.
   PubMed Web of Science ®Google Scholar
• Gruppo Italian° per lo studio della streptochinasi nellinfarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986: 397–401.
   Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–360.
   Google Scholar
• Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction; Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322.
   Google Scholar
• GISSI-2; A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65-7L
   Google Scholar
• ISIS-3; A randomised comparison of streptokinase versus tissue plasminogen activator versus antistreplase and of aspirin plus heparin versus aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–770.
   PubMed Web of Science ®Google Scholar
• The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.
   PubMed Web of Science ®Google Scholar
• The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The BER0-2 randomised trial. Lancet 2001; 358: 1855–1863.
   Google Scholar
• The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO HI) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–1123.
   Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction; The ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–722.
   Google Scholar
• The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin; The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 338: 605–613.
   Google Scholar
• Verheugt FWA, Brouwer MA. Half dose lytic plus abciximab compared to full dose lytic in acute myocardial infarction; A meta-analysis. Eur Heart J 2002; 23 Abstract Suppl: 637.
   Google Scholar
• The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Iffi/IIIa inhibition; The GUSTO V randomised trial. Lancet 2001; 357: 1905–1914.
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardissino D, Betriu A, et al. Task Force Report Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28–66.
   PubMed Web of Science ®Google Scholar
• Smalling RW, Bode C, Kalblleisch I, et al. More rapid, complete, and stable coronary thrombolysis achieved with double-bolus reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725–2732.
   PubMed Web of Science ®Google Scholar
• The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO lib) angioplasty substudy investigators. A clinical trial comparing primary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1197; 336: 1621-1628.
   Google Scholar
• Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction; A quantitative review. JAMA 1997; 278: 2093–2098.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction; A quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.
   Google Scholar
• Auer J, Berent R, Weber T, Eber B. Submission to correspondence. Primary angioplasty or thrombolysis for acute myocardial infarction? Lancet 2003; 361: 965–966. Submission to correspondence.
   Google Scholar
• Melandri G. Submission to correspondence. Lancet 2003; 361: 966.
   PubMedGoogle Scholar
• Steinbuhl SR, Berger PB, Mann JT, et al. Early and sustained dual oral platelet therapy following percutaneous coronary intervention. A randomised controlled trial. JAMA 2002; 288: 2411–2420.
   PubMed Web of Science ®Google Scholar
• Steinbuhl SR Antiplatelet agents in cardiology; the choice of therapy. Ann Thorac Surg 2000; Suppl 2: 53–58.
   Google Scholar
• Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity - dependent antithrombotic efficacy. Thromb Res 2001; 104: 149–174.
   Google Scholar
• Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction; The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility TriaL J Am Coll Cardiol 1999; 34: 1954–1962.
   PubMed Web of Science ®Google Scholar
• Neumann F-J, Blasini R, Scmitt C, et al. Effect of glycoprotein Hb/HIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695–2701.
   Google Scholar
• Montalescot G, Barragan P. Wittenberg 0, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.
   Google Scholar
• Caselia G, Caapechi A, Ottani 0, et al. Facilitated PTCA in acute myocardial infarction. A meta-analysis of available studies. Eur Heart J 2002; 23: 24 Oral presentation at ESC, Berlin, 1 September 2002.
   Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Amesen H. Warfarin, aspirin, or both after myocardial infarction. New Engl J Med 2002; 347: 969–974.
   Google Scholar
• van Es RF, Jonker JJ, Verheugt FWA, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study); A randomised clinical trial. Lancet 2002; 360: 109–111
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I; Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
   Google Scholar